Anticoagulants: Major Advances Without Clear Consensus

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Abstract

Abstract Therapeutics for thrombosis were discovered because of observations made nearly one hundred years ago. The mainstays of these treatments have been either heparin or warfarin, with the latter being preferred for long-term anticoagulation. In the last six years, newer agents with antigoagulant activities have been approved for clinical use. These agents have advantages and disadvantages over warfarin and consensus for their use is still being formed, as is the manner in which the more traditional agents, such as warfarin, should be used and monitored.

Original languageEnglish (US)
Pages (from-to)116-118
Number of pages3
JournalClinical pharmacology and therapeutics
DOIs
StatePublished - Aug 1 2016

Fingerprint

Warfarin
Anticoagulants
Heparin
Thrombosis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{20df0a13cd5a4e37a35b3637688f89c3,
title = "Anticoagulants: Major Advances Without Clear Consensus",
abstract = "Abstract Therapeutics for thrombosis were discovered because of observations made nearly one hundred years ago. The mainstays of these treatments have been either heparin or warfarin, with the latter being preferred for long-term anticoagulation. In the last six years, newer agents with antigoagulant activities have been approved for clinical use. These agents have advantages and disadvantages over warfarin and consensus for their use is still being formed, as is the manner in which the more traditional agents, such as warfarin, should be used and monitored.",
author = "Hohl, {R. J.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/cpt.399",
language = "English (US)",
pages = "116--118",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

Anticoagulants : Major Advances Without Clear Consensus. / Hohl, R. J.

In: Clinical pharmacology and therapeutics, 01.08.2016, p. 116-118.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Anticoagulants

T2 - Major Advances Without Clear Consensus

AU - Hohl, R. J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Abstract Therapeutics for thrombosis were discovered because of observations made nearly one hundred years ago. The mainstays of these treatments have been either heparin or warfarin, with the latter being preferred for long-term anticoagulation. In the last six years, newer agents with antigoagulant activities have been approved for clinical use. These agents have advantages and disadvantages over warfarin and consensus for their use is still being formed, as is the manner in which the more traditional agents, such as warfarin, should be used and monitored.

AB - Abstract Therapeutics for thrombosis were discovered because of observations made nearly one hundred years ago. The mainstays of these treatments have been either heparin or warfarin, with the latter being preferred for long-term anticoagulation. In the last six years, newer agents with antigoagulant activities have been approved for clinical use. These agents have advantages and disadvantages over warfarin and consensus for their use is still being formed, as is the manner in which the more traditional agents, such as warfarin, should be used and monitored.

UR - http://www.scopus.com/inward/record.url?scp=84978130218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978130218&partnerID=8YFLogxK

U2 - 10.1002/cpt.399

DO - 10.1002/cpt.399

M3 - Editorial

C2 - 27393187

AN - SCOPUS:84978130218

SP - 116

EP - 118

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -